Clinical trials
Observational Hemorrhage trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 9 |
| Completed | 4 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| First Affiliated Hospital Xi'an Jiaotong University | 2 |
| Beijing Anzhen Hospital | 1 |
| Beijing Chao Yang Hospital | 1 |
| Beijing Tiantan Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| First Affiliated Hospital of Ningbo University | 1 |
| General Hospital of Shenyang Military Region | 1 |
| Huazhong University of Science and Technology | 1 |
| Lanzhou University Second Hospital | 1 |
| Peking Union Medical College Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemorrhage | 20 |
| Acute Coronary Syndrome | 2 |
| Cerebral Hemorrhage | 2 |
| Ischemic Stroke | 2 |
| Liver Cirrhosis | 2 |
| Thrombosis | 2 |
| Venous Thrombosis | 2 |
| Arteriovenous Malformations | 1 |
| Atrial Fibrillation | 1 |
| Colonic Neoplasms | 1 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.